Ascendis Pharma Reports Durable 214-Week Data From TransCon PTH Phase 2 Trial In Hypoparathyroidism

Ascendis Pharma A/S has released Week 214 data from its Phase 2 PaTH Forward Trial, confirming that long-term treatment with TransCon PTH (palopegteriparatide) continues to deliver durable clinical benefits in adults with hypoparathyroidism. These results were introduced by Dr. Andrea Palermo to the 2025 ESPE & ESE Joint Congress, as a practitioner at Campus Bio-Medico University in Rome. The trial started as a 4 week double blind, placebo-controlled phase followed by open open-label extension to Week 266.

Aimee Shu, M.D. Executive Vice President of Endocrine & Rare Disease Medical Science and Chief Medical Officer at Ascendis Pharma, said, “We set out to address the underlying cause of disease and are pleased to see this long-term data reinforcing the safety profile and durability of response in patients treated with TransCon PTH, including sustained normalization of skeletal dynamics and significant and sustained improvements in kidney function.”

At Week 214, 98% of patients maintained normal serum calcium levels, and 93% remained free from conventional therapies (defined as using <600mg/day of calcium supplements and no active vitamin D). Additionally, bone health showed positive trends: bone turnover markers CTx and P1NP rose early, then stabilized above baseline; bone mineral density (BMD) remained within normal age- and sex-matched ranges. Renal function also improved, with nearly 68% of participants showing a clinically meaningful increase in eGFR.

TransCon PTH proved to be well tolerated, without a new safety signal being noted. TEAEs were generally mild to moderate and no serious adverse events were associated with the drug.